| Nov 21 |
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
|
| Nov 12 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
|
| Nov 7 |
Notice of General Meeting
|
| Oct 17 |
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
|
| Oct 15 |
Biodexa announces successful appeal of Nasdaq delisting
|
| Oct 15 |
Biodexa Announces Successful Appeal of Nasdaq Delisting
|
| Oct 4 |
Biodexa reports updated Phase 1 data from glioblastoma study
|
| Oct 4 |
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
|
| Sep 27 |
Biodexa Pharmaceuticals GAAP EPS of -0.10p
|
| Sep 26 |
Interim results for the six months ended June 30, 2024
|
